•Potent anti-tumor effects on primary BCas and brain lesions that express p95HER2•Unlike TCBs targeting HER2 the p95HER2-TCB had no impact on nontransformed cells that do not overexpress HER2. This evidence concerns the gene ERBB2 and neoplasm.